Clinical trial
Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer
NCT00022620 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Completed
Key facts
| NCT number | NCT00022620 |
|---|---|
| Title | Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer |
| Official title | Phase II Study On Paclitaxel In Recurrent Uterine Papillary Serous Carcinoma (UPSC) |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Endometrial Cancer |
| Intervention type | Drug |
| Interventions | paclitaxel |
| Start date | Jun 1, 2001 |
| Primary completion | Oct 1, 2002 |
| First posted | Jan 27, 2003 |
| Last update posted | Sep 24, 2012 |
| Countries | Austria, Belgium, Italy, Portugal, Spain, United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: